en.wikipedia.org/wiki/Bruesewitz_v._Wyeth

Bruesewitz v. Wyeth, 562 U.S. 223 (2011), is a United States Supreme Court case that decided whether a section of the National Childhood Vaccine Injury Act of 1986 preempts all vaccine design defect claims against vaccine manufacturers .

supreme.justia.com/cases/federal/us/562/223

Feb 22, 2011 ... BRUESEWITZ et al. v. WYETH LLC, fka WYETH, INC., et al. certiorari to ... Held: The NCVIA preempts all design-defect claims against vaccine ...

www.scotusblog.com/case-files/cases/bruesewitz-v-wyeth

Holding: The National Childhood Vaccine Injury Act, which created a no-fault program to provide compensation for vaccine-related injuries, preempts all ...

scholarship.law.cornell.edu/cgi/viewcontent.cgi?article=1312&context=cjlpp

Apr 21, 2009 ... 15 See James M. Wood et al., Product Liability Protection for Stem Cell Research and ...... FDA preemption and common law tort claims is Wyeth v. ...... 389 See DEBBIE BOoKCHiN & JIM SCHUMACHER, THE VIRUS AND ...

caselaw.findlaw.com/ca-court-of-appeal/1376645.html

William F. Bothwell et al., Plaintiffs and Appellants, v. ... J. Thomasch, Richard W. Mark, and Lauren J. Elliot for Defendant and Respondent Wyeth. ... Matthew A. Schumacher and John W. Shaw, Los Angeles, for Defendant and Respondent ...

clincancerres.aacrjournals.org/content/clincanres/14/4/1167.full.pdf

Feb 15, 2008 ... Rapamycin (Wyeth Pharmaceuticals) was diluted in a ... After 2 months of treatment, all mice were ..... Schumacher V,Vogel T, Leube B, et al.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4305681

Sirolimus and tacrolimus were generously provided by Wyeth-Pharma GmbH ..... Guido Schumacher, Marijke Oidtmann, Dietmar Jacob, Sven Jonas, Jan M. ... Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, et al.

casetext.com/cases/pa/pasup/2006/6

Perez · insert_drive_fileCom. v. Daniels · insert_drive_fileREINHART v. SAPP · insert_drive_fileKennedy v. Butler Memorial Hosp · insert_drive_fileIn re E.T ...

arthritis-research.biomedcentral.com/articles/10.1186/ar2978

Apr 6, 2010 ... Endpoints included the proportion of all subjects with sUA <6.0 mg/dL and the proportion of ... Becker et al.; licensee BioMed Central Ltd. 2010.